SELE and cancer: The results of blocking E-selectin with uproleselan were determined in vitro—where it reduced adhesion, chemotaxis, trans-endothelial migration and stroma-induced drug resistance and in animal models—where it induced stem and cancer cell mobilization from the BM to circulation and resensitized cancer cells to chemotherapies.